Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of HSK50042 tablets in idiopathic pulmonary fibrosis
CTR20262845Phase 2Active
- Sponsor
- Haisco-Sirnaomics
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HSK50042 in idiopathic pulmonary fibrosis (IPF), sponsored by Haisco-Sirnaomics. Started Jul 2026; status: active.
02
Drugs
HSK50042
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on CTR20262845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262845.